tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Cory Kasimov, 33 are a HOLD (31.13%), 69 are a BUY (65.09%), 4 are a SELL (3.77%).
Analyst Cory Kasimov, currently employed at EVERCORE, carries an average stock price target met ratio of 66.66% that have a potential upside of 28.79% achieved within 302 days. Previously, Cory Kasimov worked at JPMORGAN.
Cory Kasimov’s has documented 231 price targets and ratings displayed on 25 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on BMRN, Biomarin Pharmaceutical at 06-Aug-2024.
Analyst best performing recommendations are on EDIT (EDITAS MEDICINE).
The best stock recommendation documented was for CLVS (CLOVIS ONCOLOGY) at 10/31/2018. The price target of $16 was fulfilled within 7 days with a profit of $4.37 (37.58%) receiving and performance score of 53.68.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$23
$8.13 (54.67%)
$30
1 months 29 days ago
0/3 (0%)
$7.28 (46.31%)
Buy
$27
$12.13 (81.57%)
$27
1 months 29 days ago
8/21 (38.1%)
$11.28 (71.76%)
119
Buy
$20
$5.13 (34.50%)
$28
2 months ago
16/21 (76.19%)
$4.83 (31.84%)
184
Buy
$28
$13.13 (88.30%)
$30
2 months ago
0/3 (0%)
$12.83 (84.57%)
Buy
$28
$13.13 (88.30%)
$37
2 months ago
25/36 (69.44%)
$12.83 (84.57%)
486
Which stock is Cory Kasimov is most bullish on?
Which stock is Cory Kasimov is most reserved on?
What Year was the first public recommendation made by Cory Kasimov?
